Century Therapeutics gets Nasdaq extension to Feb 2026 for bid price compliance; transfers to Capital Market

Century Therapeutics, Inc.

Received 180-day extension until Feb 23, 2026 to meet $1.00 minimum bid price rule after Aug 26 initial deadline.
Nasdaq approved transfer from Global Select to Capital Market effective Aug 27, 2025; stock continues under IPSC.
Company will consider a reverse stock split to cure the bid price deficiency.
No assurance of regaining compliance; delisting remains possible if price fails to close at $1.00 for 10 consecutive days.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.